SC 262
Alternative Names: SC-262; SC-263Latest Information Update: 05 Mar 2024
At a glance
- Originator Sana Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Preclinical Chronic lymphocytic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 03 May 2024 Phase-I clinical trials in Diffuse large B cell lymphoma (Second-line therapy or greater) in USA (IV) , (NCT06285422)
- 03 May 2024 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV) (NCT06285422)
- 09 Jan 2024 Sana Biotechnology plans a clinical trial for B-cell malignancies (Second-line therapy or greater)